特発性過眠症の成人患者における Pitolisant の安全性と有効性を評価する第 3 相試験
特発性過眠症の成人患者におけるピトリサントの安全性と有効性を評価するための、二重盲検、プラセボ対照、ランダム化離脱研究
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in participants with idiopathic hypersomnia (IH) age ≥18 years.
Key secondary objectives of this study are to assess the impact of pitolisant on:
- Overall symptoms of IH
- Participant impression of overall change in their symptoms of IH
- Investigator assessment of overall disease severity of IH
Other secondary objectives of this study are to assess the impact of pitolisant in participants with IH on:
- Participant impression of overall severity of their EDS
- Functional status and activities of daily living
- Sleep-related impairment
- Sleep inertia
- Cognitive function
調査の概要
詳細な説明
This is a double-blind, placebo-controlled, randomized withdrawal study in adult participants (ages ≥18 years) with IH. The study will consist of a Screening Period (up to 28 days), an 8-week Open-Label Phase, and a 4-week Double-Blind Randomized Withdrawal Phase.
The Open-Label Phase of the study will be 8 weeks, which includes a 6-week Dose Optimization Period and a 2-week Stable Dose Period. In the Dose Optimization Period, all participants will be titrated to their optimal dose of open-label pitolisant (17.8 milligrams [mg] or 35.6 mg) based on Investigator assessment of tolerability and efficacy. The 3-week titration period will be followed by 3 weeks of flexible dosing (weeks 4-6) during which participants will continue to receive their optimal dose of 17.8 mg or 35.6 mg open-label pitolisant. Participants taking a strong cytochrome P450 2D6 (CYP2D6) inhibitor will be allowed in the study; however, for these participants, the maximum permitted daily dose of pitolisant will be 17.8 mg. Following completion of the 6-week Dose Optimization Period, participants will enter the 2-week Stable Dose Period. During this period, participants will remain at their optimal dose (the same dose they were taking at the end of the Dose Optimization Period [17.8 mg or 35.6 mg]) of open-label pitolisant for 2 weeks; dose adjustments are not allowed during the Stable Dose Period. At the end of the Stable Dose Period, participants will be defined as responders or non-responders. Responders will be randomized in a 1:1 ratio to receive blinded study drug (pitolisant or matching placebo) in the Double-Blind Randomized Withdrawal Phase of the study. Non-responders will not be randomized to treatment in the Double-Blind Randomized Withdrawal Phase and will complete two safety follow-up telephone contacts (TCs) at 15 (±3) days and 30 (+3) days after their final dose of open-label pitolisant.
During the Double-Blind Randomized Withdrawal Phase, participants (approximately 64 participants per treatment group) will receive blinded study drug either at the same dose they were taking in the Stable Dose Period (17.8 mg or 35.6 mg pitolisant) or matching placebo. The duration of the Double-Blind Randomized Withdrawal Phase will be 4 weeks (weeks 9-12); dose adjustments are not permitted during this phase of the study. After completion of the Double-Blind Randomized Withdrawal Phase (End-of Treatment Visit is on Day 84, the last day of blinded treatment), participants will complete two safety follow-up TCs with the site at 15 (±3) days and 30 (+3) days after their final dose of blinded study drug, which will include assessment for adverse events and concomitant medication use; alternatively, participants will have the opportunity to enroll in a long-term, open-label safety study under a separate protocol. Participants who opt to enroll into the long-term, open-label study will not complete the 15-day and 30-day follow-up TCs.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Peoria、Arizona、アメリカ、85381
- Phoenix Medical Group
-
Scottsdale、Arizona、アメリカ、85259
- Mayo Clinic
-
-
California
-
Los Angeles、California、アメリカ、90095
- University of California- Los Angeles
-
Los Angeles、California、アメリカ、90048
- Cedars-Sinai Medical Towers
-
San Ramon、California、アメリカ、94583
- Sleep Medicine Specialists of California
-
Santa Ana、California、アメリカ、92705
- SDS Clinical Trials Inc.
-
Santa Monica、California、アメリカ、90404
- Santa Monica Clinical Trials
-
-
Colorado
-
Boulder、Colorado、アメリカ、80301
- Alpine Clinical Research Center
-
-
Connecticut
-
Norwalk、Connecticut、アメリカ、06850
- Norwalk Hospital Sleep Center
-
-
Florida
-
Brandon、Florida、アメリカ、33511
- Meris Clinical Research
-
Clearwater、Florida、アメリカ、33765
- St. Francis Medical Institute
-
Miami、Florida、アメリカ、33126
- Sleep Medicine Specialists of South Florida, PA
-
St. Petersburg、Florida、アメリカ、33763
- Pasadena Center For Medical Research, LLC
-
Winter Park、Florida、アメリカ、32789
- Florida Pediatric Research Institute
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30328
- Neurotrials Research Inc.
-
Gainesville、Georgia、アメリカ、30501
- The Neurological Center of North GA
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Glenview、Illinois、アメリカ、60026
- NorthShore Uni HealthSys-Glenbrook Hospital
-
Peoria、Illinois、アメリカ、61637
- OSF HealthCare Saint Francis Medical Center
-
-
Maryland
-
Chevy Chase、Maryland、アメリカ、20815
- Helene A. Emsellem MD PC
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Boston Children's Hospital
-
Newton、Massachusetts、アメリカ、02459
- Neurocare, INC
-
-
Michigan
-
Novi、Michigan、アメリカ、48377
- Henry Ford Health System
-
Portage、Michigan、アメリカ、49024
- Bronson Sleep Health
-
Sterling Heights、Michigan、アメリカ、48314
- Clinical Neurophysiology Services
-
-
Minnesota
-
Edina、Minnesota、アメリカ、55125
- Minnesota Lung Center
-
Woodbury、Minnesota、アメリカ、55125
- Minnesota Lung Center
-
-
Missouri
-
Chesterfield、Missouri、アメリカ、63017
- St. Luke's Sleep Medicine and Research Center
-
St Louis、Missouri、アメリカ、63123
- Clayton Sleep Institute
-
-
Nebraska
-
North Platte、Nebraska、アメリカ、69101
- Great Plains Health
-
-
New Jersey
-
West Long Branch、New Jersey、アメリカ、07764
- Neurology Specialists of Monmouth County, PA
-
-
New York
-
New Hyde Park、New York、アメリカ、11042
- Northwell Health
-
-
North Carolina
-
Denver、North Carolina、アメリカ、28037
- Research Carolina Elite LLC
-
Durham、North Carolina、アメリカ、27705
- Duke University School of Medicine
-
Gastonia、North Carolina、アメリカ、28054
- Clinical Research of Gastonia
-
Huntersville、North Carolina、アメリカ、28078
- ARSM Research
-
-
Ohio
-
Canton、Ohio、アメリカ、44718
- NeuroScience Research Center, LLC
-
Cincinnati、Ohio、アメリカ、45245
- Intrepid Research, LLC
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
Cleveland、Ohio、アメリカ、44106
- Rainbow Babies Children's Hospital
-
Dublin、Ohio、アメリカ、43017
- Ohio Sleep Medicine and Neuroscience Institute
-
Middleburg、Ohio、アメリカ、44130
- North Star Medical Research
-
-
Oklahoma
-
Ardmore、Oklahoma、アメリカ、73401
- CardioVoyage
-
-
Pennsylvania
-
Paoli、Pennsylvania、アメリカ、19301
- Brian Abaluck, LLC
-
Willow Grove、Pennsylvania、アメリカ、19090
- Abington Neurological Associates
-
Wyomissing、Pennsylvania、アメリカ、19610
- Respiratory Specialists
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina- Institute of Psychiatry
-
Columbia、South Carolina、アメリカ、29201
- Bogan Sleep Consultants
-
North Charleston、South Carolina、アメリカ、29406
- Lowcountry Lung Critical Care
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37421
- Advanced Center for Sleep Disorders
-
Cordova、Tennessee、アメリカ、38018
- Neurology Clinic, P.C.
-
-
Texas
-
Austin、Texas、アメリカ、78731
- FutureSearch Trials of Neurology LP
-
Round Rock、Texas、アメリカ、78681
- Central Texas Neurology Consultants, PA
-
Sugar Land、Texas、アメリカ、77478
- Comprehensive Sleep Medicine Associates
-
Tomball、Texas、アメリカ、77375
- Northwest Houston Neurology and Sleep
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23507
- Children's Hospital of the King's Daughter
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University - Department of Neurology
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53719
- University of Wisconsin-Madison
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Is able to provide voluntary, written informed consent.
-
Has a current diagnosis of IH per International Classification of Sleep Disorders Third Edition criteria.
-
Male or female participant age ≥18 years at the time of Screening.
-
Has an Epworth Sleepiness Scale score of ≥12 at Screening and at Baseline (Visit 2).
-
Has a Patient Global Impression of Severity score of moderate, severe, or very severe at Screening and at Baseline (Visit 2).
-
For participants being treated for obstructive sleep apnea (OSA) or other hypoventilatory conditions, participants must be compliant as demonstrated by bilevel positive airway pressure/continuous positive airway pressure (BiPAP/CPAP) therapy with 30 days of data showing ≥4 hours of BiPAP/CPAP therapy per night for ≥70% of nights. If not on BiPAP/CPAP therapy, participants being treated for OSA must be compliant as determined by the Investigator with their medical device or oral appliance. Data must be from within 90 days prior to the Screening visit. Participants must agree to maintain compliance with their treatment for OSA throughout the duration of the study.
-
If on a treatment that could affect daytime sleepiness (including but not limited to oxybates, stimulants, modafinil, and armodafinil):
- Must be on a stable dose for at least 2 months prior to Screening and agree to continue the stable dose for the duration of the study.
- If not on a stable dose for 2 months prior to Screening, washout for 5 half-lives or 14 days, whichever is longer, prior to Day 1 and agree to remain off these treatments until completion of the study.
-
A participant who is a female of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy test at the Baseline Visit (Visit 2) and at the end of the Stable Dose Period (Visit 4) and agree to remain abstinent or use an effective method of non-hormonal contraception to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.
-
Must have a negative result on urine drug screen at the Screening Visit, Baseline Visit (Visit 2) and at the end of the Stable Dose Period (Visit 4), except for medications that are prescribed by a healthcare provider for medical conditions.
-
In the opinion of the Investigator, the participant is capable of understanding and complying with the protocol and administration of oral study drug.
Exclusion Criteria:
- Has hypersomnia due to another medical disorder (for example, narcolepsy).
- Has an Apnea Hypopnea Index of ≥10 as determined by the most recent sleep study or BiPAP/CPAP device readout.
- Has a clinically significant hypoventilatory condition as determined by the Investigator.
- Has a primary diagnosis of a psychiatric illness that is not well controlled.
- Participants taking antidepressants who have not been on a stable dose of their antidepressant for at least 12 weeks prior to Screening; participants on a stable dose of their antidepressant for at least 12 weeks prior to Screening must agree to continue their stable dose for the duration of the study.
- Experiences a mean of <6 hours of sleep per night based on sleep diary during Screening (participants need to record at least 7 nights within a 10-day period in their sleep diary within 14-days prior to the Baseline Visit [Visit 2]).
- Consistently consumes >600 mg of caffeine per day and is unable/unwilling to reduce caffeine intake to ≤600 mg per day for the duration of the study.
- Does not agree to discontinue any prohibited medication or substance listed in the protocol.
- Is currently or has previously used pitolisant.
- Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 21 days after final dose of study drug.
- Participation in an interventional research study involving another investigational medication, device, or behavioral treatment within 28 days or within 5 half-lives of the investigational medication (whichever is longer) prior to Screening.
- Has a diagnosis of end-stage renal disease (estimated glomerular filtration rate [eGFR] of <15 milliliters [mL]/minute/1.73 square meter [m^2]) or severe hepatic impairment (Child-Pugh C).
- Has a diagnosis of moderate or severe renal impairment (eGFR ≥15 to ≤59 mL/minute/1.73 m^2) or moderate hepatic impairment (Child-Pugh B) at Screening or at any time during the study.
- Has a history of long corrected QT interval syndrome or corrected QT interval using Fridericia's formula (QTcF) >450 milliseconds (msec) for males or >470 msec for females (QTcF = QT / 3√ RR) at Screening.
- Is receiving and is unable to discontinue a medication known to prolong the QT interval.
- Is receiving a concomitant medication that is known to be a strong cytochrome P450 3A4 inducer, or a centrally acting histamine 1 receptor antagonist; participants who undergo a washout of these medications of at least 5 half-lives or one week (whichever is longer) may be enrolled in the study. Use of strong CYP2D6 inhibitors is allowed; however, for these participants the maximum permitted daily dose of pitolisant is 17.8 mg.
- Is a known CYP2D6 poor metabolizer.
- Has abnormal laboratory values at Screening that are clinically significant as determined by the Investigator.
- Has initiated any new or change in allied health therapies or interventions that can interfere with the study outcomes within 28 days prior to Screening and at any time during the study, based on the Investigator's judgment.
- Has a current or recent (within 1 year) history of a substance use disorder or dependence disorder, including alcohol, tobacco, and caffeine use disorders as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.
- Has planned surgery during the study.
- Has a significant risk of committing suicide or suicidality based on history; routine psychiatric examination; Investigator's judgment; or an answer of "yes" on any question other than questions 1 to 3 (for the previous month) or "yes" on any question in the suicidal behavior section (for the past year) of the Columbia-Suicide Severity Scale, Baseline/Screening.
- Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to an unstable or uncontrolled medical condition or one that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the participant, or compromise the integrity of the study. This exclusion criterion applies not only to entry into the study, but also to continuation in the study, should such an unstable, uncontrolled, or serious medical condition arise.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Double-blind Pitolisant
Double-blind pitolisant administered once daily in the morning upon wakening for 4 weeks during the Double-Blind Randomized Withdrawal Phase |
Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant. Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant. |
|
プラセボコンパレーター:Double-blind Placebo
Matching placebo administered once daily in the morning upon wakening for 4 weeks during the Double-Blind Randomized Withdrawal Phase |
Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets. |
|
実験的:Open-label Pitolisant
Open-label pitolisant administered once daily in the morning upon wakening for 8 weeks during the Open-Label Phase |
Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 millimeters (mm) in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant. Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Epworth Sleepiness Scale (ESS) Score From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher point totals represent more severe daytime sleepiness. |
Week 8 to Week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Idiopathic Hypersomnia Severity Scale (IHSS) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms. |
Week 8 to Week 12
|
|
Proportion of Participants Who Worsened on the Patient Global Impression of Change for Idiopathic Hypersomnia (PGI-C [IH]) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The Patient Global Impression of Change for Idiopathic Hypersomnia (PGI-C [IH]) is a single-item questionnaire that assesses a participant's overall impression of the change in their symptoms of IH. The scale asks participants to rate their overall impression of the change in their symptoms of IH since a specific timepoint on a 5-point verbal rating scale ranging from "much better" to "much worse." |
Week 8 to Week 12
|
|
Change in Clinical Global Impression of Severity for IH (CGI-S [IH]) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score. |
Week 8 to Week 12
|
|
Change in Patient Global Impression of Severity Scale for Excessive Daytime Sleepiness (PGI-S [EDS]) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S [EDS]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe. |
Week 8 to Week 12
|
|
Change in Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity. |
Week 8 to Week 12
|
|
Change in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Short Form 8a (PROMIS-SRI SF 8a) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from: 1=not at all; 2=a little bit; 3=somewhat; 4=quite a bit; 5=very much, with average scores ranging from 8 to 40. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40; T-score ranges from 30 to 80.1. Higher scores represent greater impairment. |
Week 8 to Week 12
|
|
Change in Sleep Inertia Questionnaire (SIQ) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
The Sleep Inertia Questionnaire (SIQ) consists of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia. |
Week 8 to Week 12
|
|
Change in Cogstate One Back Test (ONB) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
Cognition was assessed using the Cogstate Computerized Cognitive Battery tests. The cognitive domain of working memory was assessed specifically with the One Back Test (ONB), which measures the speed of the participant's response. Results are reported as the mean of the common logarithm (log 10) transformed reaction time (in milliseconds [msec]) for correct responses. A decrease in score represents an increase in working memory performance. |
Week 8 to Week 12
|
|
Change in Cogstate Identification Test (IDN) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
Cognition was assessed using the Cogstate Computerized Cognitive Battery tests. The cognitive domain of visual attention was assessed using the Identification Test (IDN). Results reported as the mean of the log 10 transformed reaction time for correct responses. A decrease in score represents an increase in visual attention performance. |
Week 8 to Week 12
|
|
Change in Cogstate Detection Test (DET) From Week 8 to Week 12
時間枠:Week 8 to Week 12
|
Cognition was assessed using the Cogstate Computerized Cognitive Battery tests. The cognitive domain of psychomotor function was assessed specifically using the Detection Test (DET). The test measures the speed of the participant's response. Results reported as the mean of the log 10 transformed reaction time (msec) for the correct responses. A decrease in score represents an increase in psychomotor function performance. |
Week 8 to Week 12
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in ESS Score From Week 1 to Week 8
時間枠:Week 1 to Week 8
|
The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher point totals represent more severe daytime sleepiness. |
Week 1 to Week 8
|
|
Change in Idiopathic Hypersomnia Severity Scale (IHSS) Score From Week 1 to Week 8
時間枠:Week 1 to Week 8
|
The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms. |
Week 1 to Week 8
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。